We are testing the safety and effectiveness of NMD670 in adults with Type 3 spinal muscular atrophy. The study aims to see if it improves muscle strength and function compared to a placebo.
Health conditions and diseases that the clinical trial is designed to study and treat.
Spinal Muscular Atrophy Type III (SMA Type III) is a genetic condition that affects the motor neurons in the spinal cord, leading to muscle weakness and difficulty with movement, typically appearing in childhood or early adulthood.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
